Complete Wegovy vs Mounjaro UK Dosage Breakdown
Wegovy Dosage UK vs Mounjaro: Key Mechanism Differences
Understanding the fundamental differences between Wegovy dosage schedules in the UK and Mounjaro's approach begins with their distinct mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro uses tirzepatide, which targets both GIP and GLP-1 receptors for dual hormone pathway activation. The Wegovy dosage UK protocol follows a five-step escalation over 16 weeks: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance. Mounjaro's six-dose progression spans a longer timeframe with higher final doses: 2.5mg starting dose, escalating through 5mg, 7.5mg, 10mg, 12.5mg, up to 15mg maximum maintenance.
The practical implications of these different Wegovy dosage UK versus Mounjaro schedules affect both treatment duration and patient experience. Wegovy's more gradual initial escalation (four weeks at 0.25mg) may support better tolerability during the crucial first month, whilst Mounjaro's 2.5mg starting dose represents a more substantial initial intervention. Both prescription-only medicines require careful dose escalation - you cannot skip doses or accelerate the schedule. Your prescriber will determine which dosing approach aligns best with your individual weight management goals and tolerance profile.
Wegovy Dosage UK Pricing vs Mounjaro Cost Comparison
Transparent pricing comparison between Wegovy dosage UK options and Mounjaro reveals important cost considerations throughout your treatment journey. For Wegovy, single pen prices progress from £79.99 (0.25mg starter dose with FIRST40 discount code) through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience rather than savings: the Intro Duo (0.25mg & 0.5mg) costs £169.99, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) is available for £369.99. Returning customers can apply discount code DOSE25 at checkout.
Mounjaro pricing follows a different structure reflecting its distinct dosage progression and higher maintenance doses. The key advantage of purchasing both treatments through EverydayMeds is consistent cold-chain delivery, Verified Authenticity from our GPhC-registered pharmacy (#9012878), and the flexibility to switch between treatments if your prescriber recommends a change. Rather than committing to large bundle purchases initially, many patients prefer starting with single pens to assess individual response before progressing to multi-pen convenience bundles for ongoing treatment.
Clinical Evidence: Wegovy Dosage UK Effectiveness Studies
The STEP clinical trial programme demonstrates how the five-dose Wegovy dosage UK protocol performs in real-world weight management scenarios. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 2 trial specifically examined patients with type 2 diabetes, showing approximately 9.6% weight reduction with the full Wegovy dosage escalation protocol.
Long-term sustainability data from STEP 5 revealed approximately clinically studied weight loss maintained at two years, whilst the recent SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events. These results reflect the complete Wegovy dosage UK escalation from 0.25mg through to 2.4mg maintenance, emphasising that optimal outcomes require adherence to the full prescribed protocol rather than remaining on lower doses.
How Wegovy Works: GLP-1 Mechanism and Dosage Impact
Wegovy's semaglutide works as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 that your intestines release after eating. This mechanism explains why the Wegovy dosage UK escalation protocol is essential - starting at 0.25mg allows your body to adapt gradually to enhanced GLP-1 signalling. As doses increase through 0.5mg, 1mg, and 1.7mg to the final 2.4mg maintenance level, the appetite-suppressing effects become more pronounced. The medication works primarily on hypothalamic appetite centres in your brain, reducing hunger signals and promoting earlier satiety after smaller meals. Additionally, Wegovy slows gastric emptying, meaning food stays in your stomach longer, contributing to sustained fullness between meals.
Wegovy Dosage UK: Complete Ordering Process
Accessing Wegovy through our streamlined process begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our prescribing team reviews applications within 3 working days (express 24-hour service available), ensuring each Wegovy dosage UK recommendation aligns with MHRA licensing and NICE guidelines. Once approved, your prescribed dose ships via next-day cold-chain delivery, maintaining the crucial 2-8°C temperature throughout transit. Payment is processed only after prescriber approval, and all orders include detailed injection technique guidance and storage instructions. Our clinical support team remains available throughout your treatment journey for dosage queries or concerns.
Storage Advantages: Wegovy Dosage UK vs Mounjaro Practicality
Storage requirements significantly impact treatment convenience, particularly when comparing Wegovy dosage UK flexibility against Mounjaro's more restrictive parameters. Wegovy pens maintain potency for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This three-week advantage makes Wegovy particularly suitable for frequent travellers or those with inconsistent refrigerator access. All doses from 0.25mg through 2.4mg use the same FlexTouch pen design, ensuring consistent injection technique throughout your escalation journey. The pen's dose counter clearly displays your selected dose, reducing medication errors during the critical dose-escalation phase when you're transitioning between different Wegovy dosage UK levels monthly.
Wegovy Dosage UK Escalation Timeline vs Mounjaro Progression
The structured timeline comparison between Wegovy dosage UK progression and Mounjaro's schedule reveals important treatment planning considerations. Wegovy's 16-week escalation to maintenance (0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg ongoing) provides a predictable monthly progression that many patients find manageable. Mounjaro's potentially longer escalation period to reach maximum 15mg doses may extend the titration phase beyond Wegovy's timeframe.
Both treatments require patience during the initial months as your body adapts to increasing hormone levels, but the Wegovy dosage UK protocol's consistent 4-week intervals at each level provide clear milestone markers. This structured approach helps patients anticipate potential side effects, plan prescription refills, and track progress systematically. Your prescriber may occasionally recommend remaining on a sub-maximal dose if you achieve satisfactory weight management before reaching 2.4mg maintenance, demonstrating the importance of individualised dosing within the licensed Wegovy dosage UK framework.
Making Your Choice: Wegovy Dosage UK vs Mounjaro Decision Factors
The decision between Wegovy's five-dose escalation and Mounjaro's six-dose progression ultimately depends on individual medical factors, lifestyle considerations, and prescriber recommendations. Both prescription-only medicines are available through EverydayMeds with identical ordering convenience, cold-chain delivery, and ongoing clinical support from our GPhC-registered pharmacy team (#9012878). Your clinical assessment will help determine which treatment aligns with your specific circumstances, existing medical conditions, and weight management objectives. Neither medication should be considered superior without individual clinical context - both represent evidence-based approaches to weight management alongside reduced-calorie diet and increased physical activity. Our prescribing team can help you navigate this choice based on your unique medical profile and treatment preferences.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
